Simon Quick Advisors LLC Makes New Investment in 10x Genomics $TXG

Simon Quick Advisors LLC acquired a new position in 10x Genomics (NASDAQ:TXG) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 36,931 shares of the company’s stock, valued at approximately $428,000.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after acquiring an additional 1,614 shares during the period. Signaturefd LLC raised its position in shares of 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after acquiring an additional 2,409 shares during the period. Whittier Trust Co. acquired a new position in shares of 10x Genomics in the first quarter worth about $41,000. PNC Financial Services Group Inc. raised its position in shares of 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock worth $45,000 after acquiring an additional 3,119 shares during the period. Finally, US Bancorp DE raised its position in shares of 10x Genomics by 314.5% in the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock worth $52,000 after acquiring an additional 4,532 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 22,315 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the sale, the insider directly owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Trading Up 9.6%

Shares of NASDAQ TXG opened at $13.64 on Monday. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $18.21. The stock has a market cap of $1.70 billion, a PE ratio of -19.49 and a beta of 2.13. The company has a 50-day moving average of $12.84 and a 200 day moving average of $11.58.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. During the same quarter in the prior year, the company earned ($0.32) EPS. 10x Genomics’s revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, sell-side analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on TXG. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research report on Tuesday, October 14th. Barclays reissued an “overweight” rating and set a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a research note on Friday, August 8th. Morgan Stanley cut their target price on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Finally, Wall Street Zen raised shares of 10x Genomics from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $13.65.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.